|
1
|
Johnson DE, Burtness B, Leemans CR, Lui
VWY, Bauman JE and Grandis JR: Head and neck squamous cell
carcinoma. Nat Rev Dis Primers. 6:922020. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Steuer CE, El-Deiry M, Parks JR, Higgins
KA and Saba NF: An update on larynx cancer. CA Cancer J Clin.
67:31–50. 2017. View Article : Google Scholar
|
|
3
|
Sung H, Ferlay J, Siegel RL, Laversanne M,
Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020:
GLOBOCAN estimates of incidence and mortality worldwide for 36
cancers in 185 countries. CA Cancer J Clin. 71:209–249. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Siegel RL, Miller KD, Wagle NS and Jemal
A: Cancer statistics, 2023. CA Cancer J Clin. 73:17–48. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Gao W, Zhang C, Li W, Li H, Sang J, Zhao
Q, Bo Y, Luo H, Zheng X, Lu Y, et al: Promoter
methylation-regulated miR-145-5p inhibits laryngeal squamous cell
carcinoma progression by targeting FSCN1. Mol Ther. 27:365–379.
2019. View Article : Google Scholar :
|
|
6
|
Chiyomaru T, Enokida H, Tatarano S,
Kawahara K, Uchida Y, Nishiyama K, Fujimura L, Kikkawa N, Seki N
and Nakagawa M: miR-145 and miR-133a function as tumour suppressors
and directly regulate FSCN1 expression in bladder cancer. Br J
Cancer. 102:883–891. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ghebeh H, Al-Khaldi S, Olabi S, Al-Dhfyan
A, Al-Mohanna F, Barnawi R, Tulbah A, Al-Tweigeri T, Ajarim D and
Al-Alwan M: Fascin is involved in the chemotherapeutic resistance
of breast cancer cells predominantly via the PI3K/Akt pathway. Br J
Cancer. 111:1552–1561. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Liu H, Zhang Y, Li L, Cao J, Guo Y, Wu Y
and Gao W: Fascin actin-bundling protein 1 in human cancer:
Promising biomarker or therapeutic target? Mol Ther Oncolytics.
20:240–264. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Li CH, Chan MH, Liang SM, Chang YC and
Hsiao M: Fascin-1: Updated biological functions and therapeutic
implications in cancer biology. BBA Adv. 2:1000522022. View Article : Google Scholar
|
|
10
|
Li Z, Shi J, Zhang N, Zheng X, Jin Y, Wen
S, Hu W, Wu Y and Gao W: FSCN1 acts as a promising therapeutic
target in the blockade of tumor cell motility: A review of its
function, mechanism, and clinical significance. J Cancer.
13:2528–2539. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Alam H, Bhate AV, Gangadaran P, Sawant SS,
Salot S, Sehgal L, Dange PP, Chaukar DA, D'cruz AK, Kannanl S, et
al: Fascin overexpression promotes neoplastic progression in oral
squamous cell carcinoma. BMC Cancer. 12:322012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Arlt MJ, Kuzmanov A, Snedeker JG, Fuchs B,
Silvan U and Sabile AA: Fascin-1 enhances experimental osteosarcoma
tumor formation and metastasis and is related to poor patient
outcome. BMC Cancer. 19:832019. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zhao J, Zhou Y, Zhang Z, Tian F, Ma N, Liu
T, Gu Z and Wang Y: Upregulated fascin1 in non-small cell lung
cancer promotes the migration and invasiveness, but not
proliferation. Cancer Lett. 290:238–247. 2010. View Article : Google Scholar
|
|
14
|
Adams JC: Fascin-1 as a biomarker and
prospective therapeutic target in colorectal cancer. Expert Rev Mol
Diagn. 15:41–48. 2015. View Article : Google Scholar
|
|
15
|
Tan VY, Lewis SJ, Adams JC and Martin RM:
Association of fascin-1 with mortality, disease progression and
metastasis in carcinomas: A systematic review and meta-analysis.
BMC Med. 11:522013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wang L, Jia Y, Jiang Z, Gao W and Wang B:
FSCN1 is upregulated by SNAI2 and promotes epithelial to
mesenchymal transition in head and neck squamous cell carcinoma.
Cell Biol Int. 41:833–841. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Lin S, Li Y, Wang D, Huang C, Marino D,
Bollt O, Wu C, Taylor MD, Li W, DeNicola GM, et al: Fascin promotes
lung cancer growth and metastasis by enhancing glycolysis and
PFKFB3 expression. Cancer Lett. 518:230–242. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Chen C, Xie B, Li Z, Chen L, Chen Y, Zhou
J, Ju S, Zhou Y, Zhang X, Zhuo W, et al: Fascin enhances the
vulnerability of breast cancer to erastin-induced ferroptosis. Cell
Death Dis. 13:1502022. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Gao W, Zhang C, Feng Y, Chen G, Wen S,
Huangfu H and Wang B: Fascin-1, ezrin and paxillin contribute to
the malignant progression and are predictors of clinical prognosis
in laryngeal squamous cell carcinoma. PLoS One. 7:e507102012.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wu CP, Zhou L, Gong HL, Du HD, Tian J, Sun
S and Li JY: Establishment and characterization of a novel
HPV-negative laryngeal squamous cell carcinoma cell line, FD-LSC-1,
with missense and nonsense mutations of TP53 in the DNA-binding
domain. Cancer Lett. 342:92–103. 2014. View Article : Google Scholar
|
|
21
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
22
|
Huang da W, Sherman BT and Lempicki RA:
Systematic and integrative analysis of large gene lists using DAVID
bioinformatics resources. Nat Protoc. 4:44–57. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wu Y, Zhang Y, Zheng X, Dai F, Lu Y, Dai
L, Niu M, Guo H, Li W, Xue X, et al: Circular RNA circCORO1C
promotes laryngeal squamous cell carcinoma progression by
modulating the let-7c-5p/PBX3 axis. Mol Cancer. 19:992020.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Bader GD and Hogue CW: An automated method
for finding molecular complexes in large protein interaction
networks. BMC Bioinformatics. 4:22003. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Liu H, Cui J, Zhang Y, Niu M, Xue X, Yin
H, Tang Y, Dai L, Dai F, Guo Y, et al: Mass spectrometry-based
proteomic analysis of FSCN1-interacting proteins in laryngeal
squamous cell carcinoma cells. IUBMB Life. 71:1771–1784. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Ristic B, Kopel J, Sherazi S, Gupta S,
Sachdeva S, Bansal P, Ali A, Perisetti A and Goyal H: Emerging role
of fascin-1 in the pathogenesis, diagnosis, and treatment of the
gastrointestinal cancers. Cancers (Basel). 13:25362021. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zou J, Yang H, Chen F, Zhao H, Lin P,
Zhang J, Ye H, Wang L and Liu S: Prognostic significance of
fascin-1 and E-cadherin expression in laryngeal squamous cell
carcinoma. Eur J Cancer Prev. 19:11–17. 2010. View Article : Google Scholar
|
|
28
|
Durmaz A, Kurt B, Ongoru O, Karahatay S,
Gerek M and Yalcin S: Significance of fascin expression in
laryngeal squamous cell carcinoma. J Laryngol Otol. 124:194–198.
2010. View Article : Google Scholar
|
|
29
|
Guo F, Liu Y, Cheng Y, Zhang Q, Quan W,
Wei Y and Hong L: Transcriptome analysis reveals the potential
biological function of FSCN1 in HeLa cervical cancer cells. PeerJ.
10:e129092022. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Barnawi R, Al-Khaldi S, Majid S, Qattan A,
Bakheet T, Fallatah M, Ghebeh H, Alajez NM and Al-Alwan M:
Comprehensive transcriptome and pathway analyses revealed central
role for fascin in promoting triple-negative breast cancer
progression. Pharmaceuticals (Basel). 14:12282021. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Saad A, Bijian K, Qiu D, da Silva SD,
Marques M, Chang CH, Nassour H, Ramotar D, Damaraju S, Mackey J, et
al: Insights into a novel nuclear function for Fascin in the
regulation of the amino-acid transporter SLC3A2. Sci Rep.
6:366992016. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Li S, Huang XT, Wang MY, Chen DP, Li MY,
Zhu YY, Yu Y, Zheng L, Qi B and Liu JQ: FSCN1 promotes radiation
resistance in patients with PIK3CA gene alteration. Front Oncol.
11:6530052021. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Elkhatib N, Neu MB, Zensen C, Schmoller
KM, Louvard D, Bausch AR, Betz T and Vignjevic DM: Fascin plays a
role in stress fiber organization and focal adhesion disassembly.
Curr Biol. 24:1492–1499. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Villari G, Jayo A, Zanet J, Fitch B,
Serrels B, Frame M, Stramer BM, Goult BT and Parsons M: A direct
interaction between fascin and microtubules contributes to adhesion
dynamics and cell migration. J Cell Sci. 128:4601–4614.
2015.PubMed/NCBI
|
|
35
|
Ediriweera MK: Use of cholesterol
metabolism for anti-cancer strategies. Drug Discov Today.
27:1033472022. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Xu H, Zhou S, Tang Q, Xia H and Bi F:
Cholesterol metabolism: New functions and therapeutic approaches in
cancer. Biochim Biophys Acta Rev Cancer. 1874:1883942020.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Gill S, Stevenson J, Kristiana I and Brown
AJ: Cholesterol-dependent degradation of squalene monooxygenase, a
control point in cholesterol synthesis beyond HMG-CoA reductase.
Cell Metab. 13:260–273. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
You W, Ke J, Chen Y, Cai Z, Huang ZP, Hu P
and Wu X: SQLE, a key enzyme in cholesterol metabolism, correlates
with tumor immune infiltration and immunotherapy outcome of
pancreatic adenocarcinoma. Front Immunol. 13:8642442022. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Coman D, Vissers LELM, Riley LG, Kwint MP,
Hauck R, Koster J, Geuer S, Hopkins S, Hallinan B, Sweetman L, et
al: Squalene synthase deficiency: Clinical, biochemical, and
molecular characterization of a defect in cholesterol biosynthesis.
Am J Hum Genet. 103:125–130. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Luu W, Zerenturk EJ, Kristiana I, Bucknall
MP, Sharpe LJ and Brown AJ: Signaling regulates activity of DHCR24,
the final enzyme in cholesterol synthesis. J Lipid Res. 55:410–420.
2014. View Article : Google Scholar :
|
|
41
|
Dai M, Zhu XL, Liu F, Xu QY, Ge QL, Jiang
SH, Yang XM, Li J, Wang YH, Wu QK, et al: Cholesterol synthetase
DHCR24 induced by insulin aggravates cancer invasion and
progesterone resistance in endometrial carcinoma. Sci Rep.
7:414042017. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Lee GT, Ha YS, Jung YS, Moon SK, Kang HW,
Lee OJ, Joung JY, Choi YH, Yun SJ, Kim WJ and Kim IY: DHCR24 is an
independent predictor of progression in patients with
non-muscle-invasive urothelial carcinoma, and its functional role
is involved in the aggressive properties of urothelial carcinoma
cells. Ann Surg Oncol. 21(Suppl 4): S538–S545. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Jiang H, Tang E, Chen Y, Liu H, Zhao Y,
Lin M and He L: Squalene synthase predicts poor prognosis in stage
I-III colon adenocarcinoma and synergizes squalene epoxidase to
promote tumor progression. Cancer Sci. 113:971–785. 2022.
View Article : Google Scholar :
|
|
44
|
Wang S, Dong L, Ma L, Yang S, Zheng Y,
Zhang J, Wu C, Zhao Y, Hou Y, Li H and Wang T: SQLE facilitates the
pancreatic cancer progression via the lncRNA-TTN-AS1/miR-133b/SQLE
axis. J Cell Mol Med. 26:3636–3647. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Battista MC, Guimond MO, Roberge C, Doueik
AA, Fazli L, Gleave M, Sabbagh R and Gallo-Payet N: Inhibition of
DHCR24/seladin-1 impairs cellular homeostasis in prostate cancer.
Prostate. 70:921–933. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Fuller PJ, Alexiadis M, Jobling T and
McNeilage J: Seladin-1/DHCR24 expression in normal ovary, ovarian
epithelial and granulosa tumours. Clin Endocrinol (Oxf).
63:111–115. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Wu J, Guo L, Qiu X, Ren Y, Li F, Cui W and
Song S: Genkwadaphnin inhibits growth and invasion in
hepatocellular carcinoma by blocking DHCR24-mediated cholesterol
biosynthesis and lipid rafts formation. Br J Cancer. 123:1673–1685.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Du ZP, Wu BL, Xie JJ, Lin XH, Qiu XY, Zhan
XF, Wang SH, Shen JH, Li EM and Xu LY: Network analyses of gene
expression following fascin knockdown in esophageal squamous cell
carcinoma cells. Asian Pac J Cancer Prev. 16:5445–5451. 2015.
View Article : Google Scholar : PubMed/NCBI
|
